Barclays
PYXS icon

Barclays’s Pyxis Oncology PYXS Stock Holding History

Barclays’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.7K Sell
49,825
-10,560
-17% -$15.9K ﹤0.01% 4165
2025
Q4 		$69.4K Buy
60,385
+57,424
+1,939% +$203K ﹤0.01% 4672
2025
Q3 		$6.57K Sell
2,961
-1,893
-39% -$2.73K ﹤0.01% 5058
2025
Q2 		$5.34K Sell
4,854
-49,255
-91% -$55.5K ﹤0.01% 4964
2025
Q1 		$53K Sell
54,109
-22,904
-30% -$30.6K ﹤0.01% 4598
2024
Q4 		$120K Buy
77,013
+12,924
+20% +$37.3K ﹤0.01% 4549
2024
Q3 		$235K Buy
64,089
+46,997
+275% +$164K ﹤0.01% 4212
2024
Q2 		$56.6K Buy
+17,092
New +$71.9K ﹤0.01% 4158
2023
Q2 		– Sell
-118,223
Closed -$474K – 4980
2023
Q1 		$474K Sell
118,223
-829,828
-88% -$1.66M ﹤0.01% 3307
2022
Q4 		$1.27M Buy
948,051
+400
+0% +$600 ﹤0.01% 2613
2022
Q3 		$1.87M Hold
947,651
– – ﹤0.01% 1796
2022
Q2 		$2.25M Sell
947,651
-1,736
-0.2% -$4.62K ﹤0.01% 1774
2022
Q1 		$3.83M Buy
+949,387
New +$6.94M ﹤0.01% 1394

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's PYXS Position: Q1 2026 in Review

Barclays reduced its Pyxis Oncology (PYXS) stake by 17% in Q1 2026, selling an estimated $15.9K and leaving 49,825 shares worth $72.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4165.

Barclays first reported a position in PYXS in Q1 2022 and has held it in 13 quarters since. The position peaked at $3.83M in Q1 2022. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Barclays held 49,825 shares of Pyxis Oncology worth $72.7K as of Q1 2026.
  • Barclays sold 10,560 Pyxis Oncology shares in Q1 2026, an estimated $15.9K.
  • Pyxis Oncology made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4165 holding.
  • Barclays first reported a position in Pyxis Oncology in Q1 2022 and has held it in 13 quarters since.
  • Barclays's Pyxis Oncology position peaked at $3.83M in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.